ROCKET PHARMACEUTICALS, INC. business relationships
Companies named in ROCKET PHARMACEUTICALS, INC.’s 10-K filed 2026-02-26, and public companies whose annual reports name ROCKET PHARMACEUTICALS, INC.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 70 / 100 Top 1% in its category
- Agent readiness
- 40 / 100
- AI adoption
- 0 / 100
Named in ROCKET PHARMACEUTICALS, INC.’s annual report 1
“License Agreement, dated as of November 19, 2018, by and between Rocket Pharmaceuticals, Ltd. and REGENXBIO Inc. (incorporated by reference to Exhibit 10.26 to the Company's Annual Report on Form 10-K (001-36829), filed with the SEC on March 8, 2019)” SEC filing
Companies whose annual reports name ROCKET PHARMACEUTICALS, INC. 1
“...cense agreement with Nippon Shinyaku for RGX-121 and RGX-111, and (iii) NAV Technology Platform license agreements with Rocket Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc. Zolgensma and Itvisma royalties earned under the Novartis License shall only be included in the Royalty Interest aft...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.